- Amazon drought leaves Colombian border town high and dry
- Some Cubans depend on sugar water as food shortages bite
- Saudi crown prince says no Israel ties without Palestinian state
- Canada to further cut international student, foreign worker permits
- YouTube launches new TV-focused tools for creators
- White Sox heading for worst season in MLB history
- China the top challenge in US history: senior diplomat
- Hong Kong democracy tycoon's son warns time running out
- New migraine drugs no better than cheap painkillers: big study
- Sean 'Diddy' Combs again denied bail in sex trafficking case
- Brewers clinch division title as MLB playoff race heats up
- Man City blunted by 'giant' Inter in Champions League stalemate
- US stocks dip despite larger Fed interest rate cut
- Man City held by Inter as PSG pinch win in Champions League
- All Blacks recall Beauden Barrett for Australia Test
- Fears of all-out war as new Lebanon device blasts kill 20, wound 450
- Spurs late show saves Postecoglou blushes at Coventry
- PSG snatch late goal to beat Champions League debutants Girona
- Gittens' late double gives Dortmund Champions League win at Brugge
- Man City blunted by Inter in Champions League stalemate
- Hidden talent: French Olympic star Marchand opts for disguise
- MrBeast named in California lawsuit over 'Beast Games' show
- Gauff splits with Gilbert as coach after 14-month run
- Hundreds of thousands at risk in Sudan's El-Fasher: UN
- Harvey Weinstein pleads not guilty to new sex crime charge
- Venezuelan opposition candidate says letter conceding election was coerced
- Ukraine official claims Russian advance in Kursk has been 'stopped'
- X update allows app to bypass Brazil ban: internet providers
- Fears of all-out war as new Lebanon device blasts kill 14, wound 450
- US Fed makes aggressive rate cut, weeks before election
- Arsenal's Odegaard faces lengthy injury absence
- India coal expansion risks massive methane growth: report
- China the top challenge in US history, top diplomat says
- US Fed makes larger half-point cut in first reduction since 2020
- Ronaldo's Al Nassr appoint former AC Milan boss Pioli
- Ainslie 'relieved' as British book place in Louis Vuitton Cup final
- Struggling Roma replace sacked icon De Rossi with Ivan Juric
- Women's NBA will add 15th team in Portland in 2026
- Brazil fires need harsher punishment: environmental police boss
- Boeing to start large temporary furloughs amid Seattle strike
- Fears of all-out war as new Lebanon device blasts kill nine, wound 300
- 'Emergency' declared over falling UK butterfly numbers
- McIlroy outlines threats to golf peace deal
- Stock markets, dollar slip before US rate decision
- Russian advance in Kursk 'stopped': Ukraine official to AFP
- UN members demand end to 'unlawful' Israeli occupation of Palestinian territories
- Snapchat pushes 'safer' platform image, but not everyone agrees
- Three dead, 100 wounded in new wave of Lebanon device explosions
- So where does the oceans' plastic waste come from?
- Allied war heroes buried in Netherlands... 80 years on
RBGPF | 5.79% | 60.5 | $ | |
RYCEF | 1.37% | 6.55 | $ | |
VOD | 0.49% | 10.23 | $ | |
CMSC | 0.02% | 25.055 | $ | |
RELX | -0.82% | 47.37 | $ | |
GSK | -0.31% | 42.43 | $ | |
RIO | -0.02% | 62.91 | $ | |
SCS | 0.71% | 14.11 | $ | |
BTI | -0.34% | 37.88 | $ | |
AZN | 0.06% | 78.58 | $ | |
BCC | 1.33% | 137.06 | $ | |
NGG | -0.46% | 70.05 | $ | |
JRI | 0.45% | 13.44 | $ | |
CMSD | -0.12% | 24.98 | $ | |
BCE | 3.09% | 35.61 | $ | |
BP | -0.37% | 32.43 | $ |
Pfizer to seek US authorization for third Covid shot in children
Pfizer and BioNTech on Thursday announced positive results from a clinical trial on the safety and immune response of a third dose of their Covid vaccine in children aged five through 11, adding they would soon seek regulatory authorization.
Third doses of the vaccine are recommended for those aged 12 and up, and a fourth dose was recently recommended for people over 50.
Younger children -- except for those with immune compromising conditions -- have not been eligible for the third, making them more susceptible to infection from Omicron and its BA.2 subvariant.
BA.2 is now the globally dominant strain, and is behind a current spike in cases in the northeastern United States.
In the phase 2/3 trial, the companies analyzed data from 140 children aged five through 11, approximately six months after the second dose.
The dosage in this group is 10 micrograms, which was selected for safety reasons as children are more susceptible to side effects. The dose for those 12 and up is 30 micrograms.
Across the 140 children analyzed, the third dose was well tolerated, revealing no new safety concerns.
They also analyzed blood sera from a group of 30 individuals, finding that a third dose caused a 36-fold increase in levels of infection-blocking neutralizing antibodies against Omicron, compared to two doses.
Pfizer and BioNTech plan to soon submit the data to the US Food and Drug Administration (FDA), the European Medicines Agency and other regulatory agencies.
Most countries, including the United States, haven't yet authorized Covid vaccines for infants and very young children.
Last month, Moderna said it was pursuing approval for its vaccine in children aged six months through five years, using a two-dose regimen.
Pfizer's vaccine for this group was meant to be considered by the FDA in February but the agency postponed the meeting, because it wanted more data on how it would perform with three doses.
D.Schneider--BTB